Short-chain fatty acid-Butyrate ameliorates hypoxia-induced pulmonary hypertension in rat

Shixin He

the Second Xiangya Hospital of Central South University

Tengteng Zhu

the Second Xiangya Hospital of Central South University

Zhaowei Zhu

the Second Xiangya Hospital of Central South University

Yiyuan Huang

the Second Xiangya Hospital of Central South University

Shi Tai

Wuhan University Zhongnan Hospital

Liang Tang

the Second Xiangya Hospital of Central South University

Zhenfei Fang (✉ fangzhenfei@csu.edu.cn)

Second Xiangya Hospital <https://orcid.org/0000-0001-9125-5348>

Research article

Keywords: Pulmonary hypertension, Hypoxia, Intestinal microbiome, Sodium butyrate, Pulmonary artery smooth muscle cell, Proliferation

Posted Date: December 13th, 2019

DOI: <https://doi.org/10.21203/rs.2.18632/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: Gut Microbiome can produce numerous metabolites which may be absorbed into the circulation and play a critical role in the development of diseases. Our study wants to find out the roles of faecal microbiota and its metabolite in the development of pulmonary hypertension.

Methods: SD rats were exposed to either normoxia (Control, n=8) or chronic hypoxia (10% O₂) (n=16). Rats in chronic hypoxia were randomly received sodium butyrate (500 mg/kg) (n=8) or volume-matched saline (n=8) once a day. Rats in normoxia condition also received volume-matched saline once a day. RVSP and lung vascular features were assessed after 3 week's treatment. Rats' fecal samples were collected and analyzed by GCMS and 6S/18S Amplicon Sequencing. Activation of HIF-1 α , HMGB2, TLR4, TNF- α , HDAC5 and PCNA was assessed using Western blot analysis. The effect of sodium butyrate on proliferation of pulmonary artery smooth muscle cell, induced by PDGF or hypoxia (1% O₂), was evaluated by CCK-8, EDU assay and wound healing assay.

Results: Hypoxia significantly increased RVSP and induced a significant decrease in butyrate-producing bacteria, but a slight decrease of SCFAs without statistical difference. Administration of sodium butyrate remarkably attenuated the RVSP and improved lung vascular features. Decreased expression of HDAC5, PCNA, HIF-1 α , HMGB2, TLR4, TNF- α and inhibited proliferation of PASMC were found in rats or cells with sodium butyrate.

Conclusions: Decreased butyrate-producing bacteria may contribute to the development of PH, and sodium butyrate supplement can effectively attenuate hypoxia-induced PH in rats probably by inhibiting the proliferation and migration of PASMC.

Background

Pulmonary hypertension (PH) is a considerable global health issue. According to recent estimates, the prevalence of pulmonary hypertension is about 1% of the global population. When it comes to individuals aged over 65 years old, the number increases to 10%. In addition, about 80% of pulmonary hypertension patients are living in developing countries¹. It is meaningful and urgent to clarify the pathogenesis of PH. In comparison with previous belief that vasoconstriction acts as a vital role in PH pathogenesis, it is more clearly constituted that pulmonary vascular remodeling is the key causal factor of PH, which is characterized by excessive proliferation and resistance to apoptosis of PASMC and pulmonary artery endothelial cells (PAEC)². PASMC has been proved to play an important role in the development of various types of pulmonary hypertension. Different mechanisms finally lead to uncontrolled proliferation of PASMC through apoptosis resistance, activated hypoxia induced factor (HIF), histone deacetylase (HDAC) modification and inflammation, resulting in pulmonary hypertension^{3,4}.

Intestinal microbiota has been widely studied in many health problems, including cardiovascular diseases⁵. But little is known about the connection between intestinal microbiota and PH. Short-chain

fatty acids (SCFAs) are the major products of the microbial fermentative activity in the gut, especially acetate, propionate, and butyrate⁶. By analyzing Meta-genomic Data, Marius Vital et al. found that Genomes of 225 bacteria with a potential to produce butyrate were identified, including many previously unknown candidates⁷. The great majority of candidates belong to distinct families within the Firmicutes, but members of other nine phyla, especially from Actinobacteria, Bacteroidetes, Fusobacteria, Proteobacteria, Spirochaetes, and Thermotogae, were also identified as potential butyrate producers. Duncan et al and Louis et al. stated that 8 kinds of microbes, *Coprococcus comes*, *Coprococcus eutactus*, *Anaerostipes* spp, *Coprococcus catus*, *Eubacterium rectale*, *Eubacterium hallii*, *Faecalibacterium prausnitzii*, *Roseburia* spp are mainly responsible for producing butyrate in the gut and they all belong to Firmicutes^{8,9}. Callejo et al. reported that hypoxia-induced PH rats showed gut dysbiosis and among the Bacteroidetes phylum, all families were decreased in hypoxia-induced PH rats¹⁰. Our preliminary study using MCT-induced PH rat models revealed decreased number of butyrate-producing bacteria and SCFAs. Among all SCFAs, butyrate is the most diffusely investigated and has been suggested to protect against cancer and inflammation by changing cell proliferation, apoptosis and differentiation, partly because of inhibiting HDACs^{11,12}. Cantoni S et al. showed that sodium butyrate inhibited PSMCs proliferation and migration induced by PDGF¹³. In addition, Zhang et al. clarified that sodium butyrate prevented lethality of severe sepsis in rats by inhibiting high-mobility group box (HMGB) protein and TNF- α ¹⁴.

Therefore, it is important to uncover the gut microbiome changes in PH and we wonder whether sodium butyrate could reverse the elevated cell proliferation, migration and inflammation of PSMC in PH, with an aim of providing more evidence for exploring novel therapeutic targets.

Methods

Animals and experimental design

24 adult male Sprague-Dawley (SD) rats (body weight around 200g) were used. The animals were purchased from Hunan Biomodel Organism Company, Hunan, China and housed in a temperature-controlled room with a 12-h light and 12-h dark-cycles in Laboratory Animal Center of Central South University. Rats were allowed ad libitum access to water and a standard laboratory diet. They were randomly divided into three groups: 1) Control Group: rats lived in normoxic environment and were administrated with normal saline (NS) by gavage once a day; 2) Hypoxia Group: rats were continuously exposed to 10% O₂ for 3 weeks and were simultaneously intragastric administration of NS once a day; 3) Hypoxia plus Sodium Butyrate Group: rats were consecutively exposed to 10% O₂ for 3 weeks, and at the same time, they were intragastric administration of sodium butyrate (500mg/kg) once a day. Animals were weighed every other day and treatment doses were calculated accordingly. The protocol was approved by the Animal Research Committee of Central South University, Hunan, China and carried out in accordance with the Guidelines for Animal Experimentation of Central South University and the Guide for

RVSP measurement, tissue and faeces collection, tissue immunofluorescence

To measure rats' RVSP levels, they were anaesthetised (10% Chloral hydrate 0.4ml/100g i.p) and a polyethylene PE50 catheter was inserted into the right external jugular vein and threaded into the right ventricle (RV) to record the RVSP using BL-420F system. Then, the rats were euthanized by exsanguination. Following PBS perfusion, tissues and fecal samples were collected, saved in liquid nitrogen temporarily and then stored at -80°C for biochemical measurements. Parts of lung tissues were fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned. For immunofluorescence staining, the embedded tissues were cut into 5 μm -thick slices. Slices and Anti- α -smooth muscle actin (α -SMA, 1:100, ServiceBio, China) or Anti-HIF-1 α (1:100, Santacruz, USA) were incubated at 4°C overnight and then with Alexa 488 conjugated anti-rat IgG (1:200, ServiceBio, China) at room temperature for 2 hours. Finally, slices were viewed and photoed with a laser scanning confocal microscope. Relative fluorescence intensity was analyzed per lung section at a magnification of 200 using Image J software.

Cell isolation and culture

PASMC was isolated from SD rats (body weight around 150 g) with a previously described method¹⁵. Cells were cultured in complete medium consisting of DMEM/F12 supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 100 ug/mL streptomycin (all reagents from Sigma) at 37°C in a humidified atmosphere of 5% CO_2 . Some of the isolated cells were seeded on a confocal plate and the next day, cells were washed with PBS, then fixed with 4% paraformaldehyde for 10 min. Cells were then permeabilized for 15min in 0.1% Triton, and following by PBS washing, cells were incubated with anti- α -smooth muscle actin (α -SMA, 1:100, ServiceBio, China) at 4°C overnight and then with Alexa 488 conjugated anti-rat IgG (1:200, ServiceBio, China) at room temperature for 40 minutes. Finally, the cells were viewed with a fluorescence microscope to confirm that they were smooth muscle cells. For all experiments, PASMC was starved 12 hours with DMEM/F12 medium containing no serum. After 12 h, cells were induced to proliferate or migrate by replacing starvation medium with fresh DMEM/F12 medium, containing 20 ng/ml platelet-derived growth factor (PDGF) beta homodimer (PeProtech, Rocky Hill, NJ, USA) or exposed to 1% O_2 . Concurrently, sodium butyrate was dissolved in DMEM/F12 medium and added with a final concentration of 3 mmol/L; volume matched DMEM/F12 medium was added into control group. PASMC from the third to the fifth passages was used for all studies. To evaluate the proliferation ability of PASMC, CCK-8 and EDU assay were used according to the instructions.

Western Blotting

Lung tissues were homogenized in ice-cold lysis buffer with 1 mM protease inhibitor cocktail (Beyotime, China), and then centrifuged at $10,000 \times g$ for 15 min, after which the supernatants were collected. Cell protein samples were prepared and analyzed as previously described¹⁶. Briefly, cells were lysed with RIPA lysis buffer supplemented with 1 mM protease inhibitor cocktail (Beyotime, China). The protein concentrations were measured with the BCA Protein Assay kit (Beyotime, China). The total proteins were incubated in boiling water for 5 min. The quantity of protein loaded on each gel was 50 ug for lung tissues, while 20 ug for cell samples. Total proteins were separated on 8-10% SDS/PAGE gels. Then the proteins were electrophoretically transferred to polyvinylidene difluoride (PVDF) membranes. The membranes were blocked with 5% skimmed milk in PBST for 2 hours at room temperature and incubated with specific primary antibodies at 4 °C with gentle shaking, overnight. β -actin (1:5000, Proteintech, USA) was used as a loading control. Immunoreactive bands were detected using HRP-conjugated goat anti-rabbit or anti-mouse IgG (1:5000, Proteintech, USA). Then, protein bands were detected by enhanced chemiluminescence (Thermofisher, USA) and quantified by Image J software. Primary antibodies included rabbit polyclonal antibody against HDAC5 (1:1000, Proteintech, USA), rabbit polyclonal antibody against PCNA (1:2000, Proteintech, USA), rabbit polyclonal antibody against HMGB2 (1:10000, Abcam, USA), rabbit polyclonal antibody against TNF- α (1:1000, ABclonal, USA), mouse monoclonal antibody against HIF-1 α (1:200, Santacruz, USA), mouse monoclonal antibody against TLR4 (1:1000, Santacruz, USA).

CCK-8 assay

Cell proliferation was evaluated with the CCK-8 Kit, according to the manufacturer's instructions (Beyotime, China). Briefly, 10 ul CCK-8 solution was added to each well at the end of treatment and incubated for 2 h. Absorbance were collected at 450 nm with a multiwell plate reader (Thermofisher, USA).

EDU assay

PASMC was seeded and starved with DMEM/F12 medium for 12 hours, then cells were exposed to PDGF (20 ng/ml) or hypoxia (1% O₂), with or without sodium butyrate (3 mmol/l). After 48 hours, cells were treated with EDU for 2 hours. Then cells were washed with PBS and fixed in 4% paraformaldehyde for 10 min. Permeabilization was performed with 0.1% Triton for 15 min and under the circumstance of darkness, specific mixed solution was added into cells for 30 min, according to the instruction. Finally, the cells were washed with PBS again and their nuclei were labeled with 4', 6-diamidino-2-phenylindole (10 ng/mL) for 15 min and viewed with a fluorescence microscope.

Wound healing assay

For scratch wound assays, confluent cells were starved for 12 hours. Cell layers were wounded with a 1 ml micropipette tip and the floating cells were washed away with starvation medium. Then cells were stimulated with PDGF or hypoxia in the absence or presence of sodium butyrate. Untreated cells were used as a control and wound closure was monitored by a phase microscopy for 48 hours.

Fecal DNA extraction, sequencing and data processing

Fecal DNA, obtained from rats, was extracted using specific DNA-extraction kit (BGI, China) according to its instructions. Then the DNA samples were analyzed with 16S/18S Amplicon Sequencing Program, based on Illumina platform, Flash, Usearch, RDP classifier software and Greengene database, which generated the detailed information of gut microbiota in different groups.

Fecal SCFAs detection

Fecal SCFAs were measured using gas chromatography and mass spectrometry (GC-MS), as described previously¹⁷. In brief, approximately 50 mg of faeces were mixed with internal standards. Samples were analyzed using a 7890A gas chromatograph coupled with an Agilent 5975C mass selective detector (Agilent Technologies, Santa Clara, CA). A HP-5-MS (5%-diphenyl 95%-methylpolysiloxane) capillary GC column (30 m x 250 µm i.d. 2.5 µm film thickness, Agilent Technologies) was used with helium as the carrier gas at a constant flow rate of 1 mL/min. All raw data were processed with Enhanced Chemstation (Agilent Technologies) for mass spectral visualization, identification, and quantitation. The integrated areas of the SCFAs were normalized to the internal standard and quantified with a standard curve constructed from serial dilutions of SCFAs.

Statistics

Data are presented as the mean $\pm$ SD. Comparisons between multiple groups were conducted using one-way analysis of variance (ANOVA). Comparisons between two groups were conducted using Mann-Whitney t-test. In the analysis of intestinal microbiota, kruskal test was used for three groups. The difference with $P < 0.05$ (two sides) was statistically significant.

Results

1. Decreased butyrate-producing bacteria in hypoxia-induced PH rat models.

Our data showed that Firmicutes decreased in hypoxic rat models compared to the control group. At the level of Family, hypoxic rat models also showed decrease in Clostridiaceae and Erysipelotrichaceae, both pertaining to Firmicutes. However, there was no difference of butyrate content in 3 groups' faeces (Fig. 1).

2. Sodium Butyrate ameliorates pulmonary hypertension in hypoxic rat models along with HIF and HDAC inhibition.

Although in different groups, there was no accordant change between butyrate-producing bacteria and butyrate content, we still wonder whether extra supplement of butyrate could ameliorate the PH process induced by hypoxia. The results of in vivo experiment showed rats exposed to chronic hypoxia developed PH characterized by significant increased RVSP level (Fig. 2) and thickening of small pulmonary arterial wall showed by immunofluorescence of α -SMA (Fig. 3). Butyrate treatment (500 mg/kg by gavage once a day) significantly attenuated RVSP level and thickness of small pulmonary arterial wall when compared to hypoxia group. Sodium butyrate could effectively reverse the increased expression of HIF-1 α , HMGB2, TLR4, TNF- α and HDAC5, PCNA in the lungs of hypoxia-induced rats (Fig. 4). HIF-1 α immunofluorescence of rat lungs also confirmed its decreased expression in sodium butyrate group compared to hypoxia group (Fig. 5).

3. Sodium Butyrate inhibits the proliferation and migration of PASMC probably via HIF and HDAC inhibition.

We further tested the effect of butyrate on proliferation and migration of PASMC. All the results of CCK-8 and EDU immunofluorescence showed butyrate treatment (3 mmol/l) significantly decreased proliferation of PASMC induced by PDGF (20 ng/ml) or hypoxia (1% O₂) (Figs. 6, 7). Wound-healing assay manifested that sodium butyrate (3 mmol/l) inhibited the migration of PASMC, in comparison with PDGF or hypoxia (Fig. 8). Western blotting outcomes also revealed opposite effect on HIF-1 α , HMGB2, TLR4, TNF- α and HDAC5, PCNA expression with sodium butyrate compared to PDGF or hypoxia (Fig. 9).

Discussion

To our knowledge, the results of our study first demonstrated a decrease of butyrate-producing bacteria in hypoxia-induced PH rats, and supplementation of sodium butyrate could ameliorate hypoxia-induced PH in rat model, marked with attenuated RVSP level and thickness of small pulmonary arterial wall. Regrettably, this study didn't achieve statistically difference of sodium butyrate in different groups' faeces. It may be because of limited samples, selected faeces-collecting position or limited intervening time. As the important energy source and molecule for colon cells, extra supplement of sodium butyrate

may be abundantly absorbed by colon cells and exert its effects. But the exact pathway of sodium butyrate from gut to pulmonary hypertension is still worthy of investigating. In this study, we showed the decreased protein levels of HDAC5, PCNA, and HIF-1 α , HMGB2, TLR4, TNF- α with sodium butyrate, compared to hypoxia or PDGF, both in rats' lungs and PASMC. Furthermore, this study proved that sodium butyrate could effectively inhibit hypoxia or PDGF-induced proliferation of PASMC, which is partly in accordance with previous study conducted by Cantoni S et al¹³.

Zhao et al. reported increased HDAC1 and HDAC5 protein levels in lungs from both IPAH patients and hypoxia-induced PH rats¹⁸. HDAC inhibitors, valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA), prevented and reduced pulmonary hypertension of hypoxia-induced PH rats. HDAC5 belongs to class IIa HDACs, and it has long amino-terminal extensions, which act as binding sites for transcription factors and cofactors¹⁹. In muscle cells, class IIa HDACs can act on genes that govern cellular growth and differentiation^{20,21}. Our study also found increased HDAC5 expression in rats or PASMC exposed to hypoxia and sodium butyrate could reverse the increased expression. By studying HIF-1 α knock-out mice, Yu et al, and Brusselmans et al proved that increased HIF-1 α play an important role in the development of pulmonary hypertension^{22,23}. In addition, previous studies also found enhanced HIF-1 α levels in plexiform lesions of PH patients and pulmonary vasculature of chronic hypoxia mice^{24,25,26}. Compared to control, in vitro results from Malczyk et al and Veith et al, showed an over-expression of HIF-1 α with enhanced PASMC proliferation^{27,28}. Given the condition that activated HIF-1 α could accompany with switch from aerobic to anaerobic metabolism, a phenomenon known as Warburg effect, which also could be seen in pulmonary hypertension's PASMC, sodium butyrate may have an impact on PASMC metabolism under the condition of hypoxia²⁵. By studying PASMC from HIF-1 α ^{+/-} mice, Shimoda LA discovered inhibited hypoxia-induced proliferation²⁹. Several studies showed inspiring outcomes of hypoxia-induced PH by using pharmacologic inhibitors targeting HIF activity³⁰. In conclusion, there is no doubt that HIF-1 α acts a crucial role in the progress of PH. So it is meaningful to see decreased expression of HIF-1 α treatment with sodium butyrate in our study.

Lots of growth factors, cytokines and chemokines, including PDGF, have been claimed to stimulate cancer and PH occurrence^{31,32,33}. In PH patients, some studies have found elevated levels of pro-inflammatory cytokines, such as IL-6 and TNF- α , which often have a close relationship with worse clinical outcome^{34,35}. HMGB2 could enhance proliferation and migration in human aortic smooth muscle cells by inducing reactive oxygen species³⁶. Therefore, it is important for sodium butyrate to decrease the protein levels of PCNA, HMGB2, TLR4 and TNF- α , which play different roles in the development of PH and PASMC proliferation.

Our study also has some limitation. First, the study is lack of data of butyrate-producing bacteria and SCFAs in PH patients, which is our next plan. Second, in terms of molecular mechanism, there still have a lot to explore and investigate.

Conclusion

In summary, we demonstrated that decreased butyrate-producing bacteria may contribute to the development of PH, and sodium butyrate supplement can effectively attenuate hypoxia-induced PH in rats probably by inhibiting the proliferation and migration of PASMC.

Abbreviations

SD: Sprague-Dawley

RVSP: Right ventricular systolic pressure

GCMS: Gas chromatography and mass spectrometry

PH: Pulmonary hypertension

PASMC: Pulmonary artery smooth muscle cell

PAEC: Pulmonary artery endothelial cell

HIF-1 α : Hypoxia-induced factor-1 α

HMGB2: High-mobility group box 2

TLR4: Toll-like receptor 4

TNF- α : Tumor necrosis factor- α

HDAC5: Histone deacetylase 5

PCNA: Proliferating cell nuclear antigen

α -SMA: α -smooth muscle actin

PDGF: Platelet-derived growth factor

CCK-8: Cell counting kit-8

EDU: 5-Ethynyl-2'-deoxyuridine

SCFAs: Short chain fatty acids

MCT: Monocrotaline

NS: Normal saline

SB: Sodium Butyrate

Declarations

Ethics approval and consent to participate

The rats experiment protocol was approved by the Animal Research Committee of Central South University, Hunan, China and carried out in accordance with the Guidelines for Animal Experimentation of Central South University and the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication NO. 85-23, revised 2011).

Consent for publication

All the authors declare no competing interests.

Availability of data and material

The data set during and/or analyzed during the current study available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This study was funded by the National Natural Science Foundation of China (H00203, 85170267).

The funding sponsors had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.

Authors' contributions

Shixin He, Tengteng Zhu, Zhaowei Zhu, Yiyuan Huang, Shi Tai, Liang Tang and Zhenfei Fang designed the experiment. Shixin He, Zhaowei Zhu and Zhenfei Fang wrote the manuscript. Shixin He and Tengteng Zhu performed the experiments and analyzed the data. Zhaowei Zhu and Zhenfei Fang helped with data analysis and revised the manuscript. All authors reviewed the manuscript. All authors have read and approved the manuscript.

Acknowledgements

We declare that there was no commercial interest or conflict of interest for this study. We thank Doctor Fei Luo for his suggestions in revising the paper.

Author Information

Affiliations

Department of Cardiology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.

Shixin He, Tengting Zhu, Zhaowei Zhu, Yiyuan Huang, Shi Tai, Liang Tang

Corresponding author

Department of Cardiology, The Second Xiangya Hospital of Central South University, No. 139, Middle Renmin Road, Changsha, Hunan 410011, China. E-mail address: fangzhenfei@csu.edu.cn

Zhenfei Fang

References

- [1]. Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, Jing ZC and Gibbs JS. A global view of pulmonary hypertension. *Lancet Respir Med* 2016; 4: 306-322.
- [2]. Boucherat O, Vitry G, Trinh I, Paulin R, Provencher S and Bonnet S. The cancer theory of pulmonary arterial hypertension. *Pulmonary Circulation* 2017; 2: 285-299.
- [3]. de Jesus PV. Molecular pathogenesis and current pathology of pulmonary hypertension. *HEART FAILURE REVIEWS* 2016; 3: 239-257.

- [4]. Paulin R and Michelakis ED. The metabolic theory of pulmonary arterial hypertension. *CIRCULATION RESEARCH* 2014; 1: 148-164.
- [5]. Tang W, Backhed F, Landmesser U and Hazen SL. Intestinal Microbiota in Cardiovascular Health and Disease: JACC State-of-the-Art Review. *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY* 2019; 16: 2089-2105.
- [6]. Cummings JH, Pomare EW, Branch WJ, Naylor CP and Macfarlane GT. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. *GUT* 1987; 10: 1221-1227.
- [7]. Vital M, Howe AC and Tiedje JM. Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data. *mBio* 2014; 2: e889.
- [8]. Duncan SH, Barcenilla A, Stewart CS, Pryde SE and Flint HJ. Acetate utilization and butyryl coenzyme A (CoA):acetate-CoA transferase in butyrate-producing bacteria from the human large intestine. *Appl Environ Microbiol* 2002; 10: 5186-5190.
- [9]. Louis P, Hold GL and Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. *NATURE REVIEWS MICROBIOLOGY* 2014; 10: 661-672.
- [10]. Callejo M, Mondejar-Parreno G, Barreira B, Izquierdo-Garcia JL, Morales-Cano D, Esquivel-Ruiz S, Moreno L, Cogolludo A, Duarte J and Perez-Vizcaino F. Pulmonary Arterial Hypertension Affects the Rat Gut Microbiome. *Sci Rep* 2018; 1: 9681.
- [11]. Flint HJ, Scott KP, Louis P and Duncan SH. The role of the gut microbiota in nutrition and health. *Nat Rev Gastroenterol Hepatol* 2012; 10: 577-589.
- [12]. Koh A, De Vadder F, Kovatcheva-Datchary P and Backhed F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. *CELL* 2016; 6: 1332-1345.
- [13]. Cantoni S, Galletti M, Zambelli F, Valente S, Ponti F, Tassinari R, Pasquinelli G, Galie N and Ventura C. Sodium butyrate inhibits platelet-derived growth factor-induced proliferation and migration in pulmonary artery smooth muscle cells through Akt inhibition. *FEBS Journal* 2013; 9: 2042-2055.
- [14]. Zhang LT, Yao YM, Lu JQ, Yan XJ, Yu Y and Sheng ZY. Sodium butyrate prevents lethality of severe sepsis in rats. *SHOCK* 2007; 6: 672-677.
- [15]. Shimoda LA, Sylvester JT and Sham JS. Mobilization of intracellular Ca(2+) by endothelin-1 in rat intrapulmonary arterial smooth muscle cells. *Am J Physiol Lung Cell Mol Physiol* 2000; 1: L157-L164.
- [16]. Lionetti V, Cantoni S, Cavallini C, Bianchi F, Valente S, Frascari I, Olivi E, Aquaro GD, Bonavita F, Scarlata I, Maioli M, Vaccari V, Tassinari R, Bartoli A, Recchia FA, Pasquinelli G and Ventura C. Hyaluronan mixed esters of butyric and retinoic acid affording myocardial survival and repair without stem cell transplantation. *JOURNAL OF BIOLOGICAL CHEMISTRY* 2010; 13: 9949-9961.

- [17]. Cai J, Zhang L, Jones RA, Correll JB, Hatzakis E, Smith PB, Gonzalez FJ and Patterson AD. Antioxidant Drug Tempol Promotes Functional Metabolic Changes in the Gut Microbiota. *JOURNAL OF PROTEOME RESEARCH* 2016; 2: 563-571.
- [18]. Zhao L, Chen CN, Hajji N, Oliver E, Cotroneo E, Wharton J, Wang D, Li M, McKinsey TA, Stenmark KR and Wilkins MR. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. *CIRCULATION* 2012; 4: 455-467.
- [19]. Stratton MS and McKinsey TA. Acetyl-lysine erasers and readers in the control of pulmonary hypertension and right ventricular hypertrophy. *Biochemistry and Cell Biology* 2015; 2: 149-157.
- [20]. Lu J, McKinsey TA, Zhang CL and Olson EN. Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class II histone deacetylases. *MOLECULAR CELL* 2000; 2: 233-244.
- [21]. McKinsey TA, Zhang CL, Lu J and Olson EN. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. *NATURE* 2000; 6808: 106-111.
- [22]. Yu AY, Shimoda LA, Iyer NV, Huso DL, Sun X, McWilliams R, Beaty T, Sham JS, Wiener CM, Sylvester JT and Semenza GL. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. *JOURNAL OF CLINICAL INVESTIGATION* 1999; 5: 691-696.
- [23]. Brusselmans K, Compennolle V, Tjwa M, Wiesener MS, Maxwell PH, Collen D and Carmeliet P. Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. *JOURNAL OF CLINICAL INVESTIGATION* 2003; 10: 1519-1527.
- [24]. Tudor RM, Chacon M, Alger L, Wang J, Taraseviciene-Stewart L, Kasahara Y, Cool CD, Bishop AE, Geraci M, Semenza GL, Yacoub M, Polak JM and Voelkel NF. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. *JOURNAL OF PATHOLOGY* 2001; 3: 367-374.
- [25]. Bonnet S, Michelakis ED, Porter CJ, Andrade-Navarro MA, Thebaud B, Bonnet S, Haromy A, Harry G, Moudgil R, McMurtry MS, Weir EK and Archer SL. An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. *CIRCULATION* 2006; 22: 2630-2641.
- [26]. Mizuno S, Bogaard HJ, Kraskauskas D, Alhussaini A, Gomez-Arroyo J, Voelkel NF and Ishizaki T. p53 Gene deficiency promotes hypoxia-induced pulmonary hypertension and vascular remodeling in mice. *Am J Physiol Lung Cell Mol Physiol* 2011; 5: L753-L761.
- [27]. Malczyk M, Veith C, Fuchs B, Hofmann K, Storch U, Schermuly RT, Witzenrath M, Ahlbrecht K, Fecher-Trost C, Flockerzi V, Ghofrani HA, Grimminger F, Seeger W, Gudermann T, Dietrich A and Weissmann N.

- Classical transient receptor potential channel 1 in hypoxia-induced pulmonary hypertension. *Am J Respir Crit Care Med* 2013; 12: 1451-1459.
- [28]. Veith C, Zakrzewicz D, Dahal BK, Balint Z, Murmann K, Wygrecka M, Seeger W, Schermuly RT, Weissmann N and Kwapiszewska G. Hypoxia- or PDGF-BB-dependent paxillin tyrosine phosphorylation in pulmonary hypertension is reversed by HIF-1 α depletion or imatinib treatment. *Thromb Haemost* 2014; 6: 1288-1303.
- [29]. Shimoda LA. 55th Bowditch Lecture: Effects of chronic hypoxia on the pulmonary circulation: role of HIF-1. *J Appl Physiol* (1985) 2012; 9: 1343-1352.
- [30]. Abud EM, Maylor J, Udem C, Punjabi A, Zaiman AL, Myers AC, Sylvester JT, Semenza GL and Shimoda LA. Digoxin inhibits development of hypoxic pulmonary hypertension in mice. *Proc Natl Acad Sci U S A* 2012; 4: 1239-1244.
- [31]. Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, Jones PL, Maitland ML, Michelakis ED, Morrell NW, Newman JH, Rabinovitch M, Schermuly R, Stenmark KR, Voelkel NF, Yuan JX and Humbert M. Inflammation, growth factors, and pulmonary vascular remodeling. *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY* 2009; 1 Suppl: S10-S19.
- [32]. Rabinovitch M, Guignabert C, Humbert M and Nicolls MR. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. *CIRCULATION RESEARCH* 2014; 1: 165-175.
- [33]. Shalapour S and Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. *JOURNAL OF CLINICAL INVESTIGATION* 2015; 9: 3347-3355.
- [34]. Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, Duroux P, Galanaud P, Simonneau G and Emilie D. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. *Am J Respir Crit Care Med* 1995; 5: 1628-1631.
- [35]. Selimovic N, Bergh CH, Andersson B, Sakiniene E, Carlsten H and Rundqvist B. Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. *EUROPEAN RESPIRATORY JOURNAL* 2009; 3: 662-668.
- [36]. He YH, Wang XQ, Zhang J, Liu ZH, Pan WQ, Shen Y, Zhu ZB, Wang LJ, Yan XX, Yang K, Zhang RY, Shen WF, Ding FH and Lu L. Association of Serum HMGB2 Levels With In-Stent Restenosis: HMGB2 Promotes Neointimal Hyperplasia in Mice With Femoral Artery Injury and Proliferation and Migration of VSMCs. *Arterioscler Thromb Vasc Biol* 2017; 4: 717-729.

Figures

Figure 1

Analysis of butyrate-producing bacteria in faeces of rats. (A) Firmicutes (Phylum) in rats' faeces. (B) Butyrate in faeces of rats. No observed statistical difference. (C) Clostridiaceae (Family) in rats' faeces. (D) Erysipelotrichaceae (Family) in rats' faeces. The data are presented as mean±SD. * $p < 0.05$ compared with Control.

Figure 2

. Right ventricular systolic pressure (RVSP) of rats. The data are presented as mean $\pm$ SD. * $p < 0.05$ compared with Control, # $p < 0.05$ compared with Hypoxia.

Figure 3

Immunofluorescence of α -SMA in lungs of rats. The mean density of α -SMA are presented as mean $\pm$ SD. * $p < 0.05$ compared with Hypoxia. Mean density = IOD sum/AREA sum.

Figure 4

Western blotting of rats' lungs. The data are presented as mean±SD. * p<0.05 compared with Control, # p<0.05 compared with Hypoxia.

Figure 5

Immunofluorescence of HIF-1α in rats' lungs. * $p < 0.05$ compared with Hypoxia. Mean density = IOD sum/AREA sum.

Figure 6

CCK-8 of PASMOC (48 hours). The ability of proliferation = $\frac{[A450(\text{sample}) - A450(\text{blank})]}{[A450(\text{C}) - A450(\text{blank})]} \times 100\%$. C: Control, H: Hypoxia (1%O₂), P: PDGF (20 ng/ml), SB: Sodium Butyrate (3 mmol/l). The data are presented as mean $\pm$ SD. * $p < 0.05$ compared with Control, # $p < 0.05$ compared with Hypoxia, ^ $p < 0.05$ compared with PDGF.

Figure 7

A. EDU test of PASM (48 hours). PDGF (20 ng/ml): Platelet Derived Growth Factor. SB (3 mmol/l): Sodium Butyrate. B. The percentages of positive cells are presented as mean $\pm$ SD. * $p < 0.05$ compared with Control, # $p < 0.05$ compared with Hypoxia, ^ $p < 0.05$ compared with PDGF.

Figure 8

A. Cell migration of PASM (48 hours). PDGF (20 ng/ml): Platelet Derived Growth Factor. SB (3 mmol/l): Sodium Butyrate. B. The wound areas are presented as mean±SD. * p<0.05 compared with Control, # p<0.05 compared with Hypoxia, ^ p<0.05 compared with PDGF.

Figure 9

Western blotting of PASM. C: Control, S/SB: Sodium Butyrate (3 mmol/l), H: Hypoxia, P/PDGF: Platelet Derived Growth Factor (20 ng/ml). The data are presented as mean±SD. * p<0.05 compared with Control, # p<0.05 compared with Hypoxia, ^ p<0.05 compared with PDGF.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [BMC20191204theARRIVEGuidelinesChecklist2014.docx](#)